Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059182 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
A Phase 1 study, sponsored by Serum Life Science Europe.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT07059182 is a Phase 1 study that has completed, run by Serum Life Science Europe. The registered enrollment target is 30 participants.
The verdict
NCT07059182, a Phase 1 study, has completed, sponsored by Serum Life Science Europe.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if whole-cell Streptococcus pneumoniae (wSp) vaccination is safe and tolerated in healthy adults. The main aim is to evaluate the safety and tolerability of wSp vaccine. Researchers will compare wSp vaccinated participants with placebo-treated participants. Participants will be administered once with 1mg wSp vaccine or placebo. After dosing, they will be followed up for 30 days. In addition to the screening and enrollment visits, each participant will come to the study site for scheduled study visits on Days 14 and 30 to undergo study evaluations and measurements and to monitor safety. Each participant also will receive scheduled phone calls on Days 3 and 7 to monitor safety.
Interventions
- DRUG Placebo
- BIOLOGICAL Inactivated whole-cell Streptococcus pneumoniae vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07059182
The ClinicalTrials.gov registry entry for NCT07059182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Serum Life Science Europe, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07059182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07059182 about?
NCT07059182 is a clinical study titled "Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults". The goal of this clinical trial is to learn if whole-cell Streptococcus pneumoniae (wSp) vaccination is safe and tolerated in healthy adults. The main aim is to evaluate the safety and tolerability of wSp vaccine. Researchers will compare wSp vaccinated participants with placebo-treated participant...
What is the current status of trial NCT07059182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-06-11. Estimated completion is 2025-08-29.
What interventions are being tested in trial NCT07059182?
The interventions under investigation include: Placebo (DRUG), Inactivated whole-cell Streptococcus pneumoniae vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07059182?
This trial is sponsored by Serum Life Science Europe, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.